This is a commentary on AI regulation, not a concrete new development. It discusses potential impacts and industry concerns without reporting a specific event.

Securing FDA Priority Review for Enhertu in the neoadjuvant setting for early-stage HER2-positive breast cancer could significantly expand its market share. This positions AstraZeneca to capture a larger patient population earlier in the treatment journey, potentially displacing existing therapies and solidifying Enhertu's blockbuster status.